WEKO3
アイテム
{"_buckets": {"deposit": "d4a501ab-99c4-40fc-bd8a-eed3b0126c1d"}, "_deposit": {"created_by": 15, "id": "14151", "owners": [15], "pid": {"revision_id": 0, "type": "depid", "value": "14151"}, "status": "published"}, "_oai": {"id": "oai:sapmed.repo.nii.ac.jp:00014151", "sets": ["2035"]}, "author_link": ["23234", "23235", "23236", "23237", "23238", "23239", "23240", "23241", "23242"], "item_7_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2010", "bibliographicIssueDateType": "Issued"}, "bibliographicPageEnd": "31", "bibliographicPageStart": "21", "bibliographicVolumeNumber": "45", "bibliographic_titles": [{"bibliographic_title": "Tumor Research"}, {"bibliographic_title": "Tumor Research", "bibliographic_titleLang": "en"}]}]}, "item_7_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Multiple myeloma continues to be a lethal malignancy despite the development of treatments such as high-dose chemotherapy combined with stem cell transplantation. Multiple myeloma arises through an accumulation of multiple genetic anges, including immunoglobulin gene rearrangements involved in Cyclin D. The main difficulties in multiple myeloma treatments are drug-resistance. DNA methylation of the5\u0027 CpG islands of genes is often found in multiple myeloma. To screen for he genes involved in tumorigenesis of multiple myeloma, which are silenced by DNA methylation, we performed cDNA microarray analysis using multiple myeloma cell lines treated with demethylating agent5-aza-2-deoxycytidine (DAC), and entified RASD1, a dexamethasone (Dex)-inducible gene, as one of the targets of epigenetic changes. Inactivation of RASD1 was found to correlate with resistance to Dex, and treatment of multiple myeloma cells with DAC restored sensitivity to Dex. These findings suggest the involvement of epigenetic gene silencing in multiple myeloma progression and drug-resistance, and the usefulness of demethylation therapy for multiple myeloma treatment. Furthermore, DNA methylation can be an epigenetic biomarker for multiple myeloma.", "subitem_description_type": "Abstract"}]}, "item_7_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.15114/tr.45.21", "subitem_identifier_reg_type": "JaLC"}]}, "item_7_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Sapporo Medical University"}]}, "item_7_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0041-4093", "subitem_source_identifier_type": "ISSN"}]}, "item_7_version_type_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Hiroshi, Yasui"}], "nameIdentifiers": [{"nameIdentifier": "23234", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tadao, Ishida"}], "nameIdentifiers": [{"nameIdentifier": "23235", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Masanori, Nojima"}], "nameIdentifiers": [{"nameIdentifier": "23236", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yuka, Aoki"}], "nameIdentifiers": [{"nameIdentifier": "23237", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hiroshi, Ikeda"}], "nameIdentifiers": [{"nameIdentifier": "23238", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hiromu, Suzuki"}], "nameIdentifiers": [{"nameIdentifier": "23239", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Toshiaki, Hayashi"}], "nameIdentifiers": [{"nameIdentifier": "23240", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yasuhisa, Shinomura"}], "nameIdentifiers": [{"nameIdentifier": "23241", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Minoru, Toyota"}], "nameIdentifiers": [{"nameIdentifier": "23242", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-07-31"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "n004140934521.pdf", "filesize": [{"value": "56.3 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 56300000.0, "url": {"label": "n004140934521.pdf", "url": "https://sapmed.repo.nii.ac.jp/record/14151/files/n004140934521.pdf"}, "version_id": "55183439-7eef-4553-863d-c53d5883b8a8"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Multiple myeloma", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Epigenetics", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "DNA methylation", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Biomarker", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Multiple myeloma", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Epigenetics", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "DNA methylation", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Biomarker", "subitem_subject_language": "en", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Epigenetic biomarkers for prediction of sensitivity to chemotherapeutic drugs in multiple myeloma", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Epigenetic biomarkers for prediction of sensitivity to chemotherapeutic drugs in multiple myeloma", "subitem_title_language": "en"}]}, "item_type_id": "7", "owner": "15", "path": ["2035"], "permalink_uri": "https://doi.org/10.15114/tr.45.21", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2019-07-31"}, "publish_date": "2019-07-31", "publish_status": "0", "recid": "14151", "relation": {}, "relation_version_is_last": true, "title": ["Epigenetic biomarkers for prediction of sensitivity to chemotherapeutic drugs in multiple myeloma"], "weko_shared_id": -1}
Epigenetic biomarkers for prediction of sensitivity to chemotherapeutic drugs in multiple myeloma
https://doi.org/10.15114/tr.45.21
https://doi.org/10.15114/tr.45.21c79bc360-4a2f-4080-9a40-f5b2ec2f85dd
名前 / ファイル | ライセンス | アクション |
---|---|---|
n004140934521.pdf (56.3 MB)
|
|
Item type | 紀要論文 / Departmental Bulletin Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-07-31 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Epigenetic biomarkers for prediction of sensitivity to chemotherapeutic drugs in multiple myeloma | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Multiple myeloma | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Epigenetics | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | DNA methylation | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Biomarker | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Multiple myeloma | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Epigenetics | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | DNA methylation | |||||
キーワード | ||||||
言語 | en | |||||
主題Scheme | Other | |||||
主題 | Biomarker | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | departmental bulletin paper | |||||
ID登録 | ||||||
ID登録 | 10.15114/tr.45.21 | |||||
ID登録タイプ | JaLC | |||||
著者 |
Hiroshi, Yasui
× Hiroshi, Yasui× Tadao, Ishida× Masanori, Nojima× Yuka, Aoki× Hiroshi, Ikeda× Hiromu, Suzuki× Toshiaki, Hayashi× Yasuhisa, Shinomura× Minoru, Toyota |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Multiple myeloma continues to be a lethal malignancy despite the development of treatments such as high-dose chemotherapy combined with stem cell transplantation. Multiple myeloma arises through an accumulation of multiple genetic anges, including immunoglobulin gene rearrangements involved in Cyclin D. The main difficulties in multiple myeloma treatments are drug-resistance. DNA methylation of the5' CpG islands of genes is often found in multiple myeloma. To screen for he genes involved in tumorigenesis of multiple myeloma, which are silenced by DNA methylation, we performed cDNA microarray analysis using multiple myeloma cell lines treated with demethylating agent5-aza-2-deoxycytidine (DAC), and entified RASD1, a dexamethasone (Dex)-inducible gene, as one of the targets of epigenetic changes. Inactivation of RASD1 was found to correlate with resistance to Dex, and treatment of multiple myeloma cells with DAC restored sensitivity to Dex. These findings suggest the involvement of epigenetic gene silencing in multiple myeloma progression and drug-resistance, and the usefulness of demethylation therapy for multiple myeloma treatment. Furthermore, DNA methylation can be an epigenetic biomarker for multiple myeloma. | |||||
書誌情報 |
Tumor Research en : Tumor Research 巻 45, p. 21-31, 発行日 2010 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0041-4093 | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
出版者 | ||||||
出版者 | Sapporo Medical University |